Oncternal Therapeutics

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression.
The pipeline includes cirmtuzumab (ROR1 antibody in Phase 1/2), TK216 (targeted ETS inhibitor in Phase 1) and ROR1 CAR-T cell therapy (in preclinical).
Ticker:
OCNT
Exchange:
Nasdaq
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
Cirmtuzumab (ROR1 mAb)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
Chief Business Officer
Oncternal Therapeutics